Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk | MicrobiomeTrials← Back to trialsNCT07619495
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-01-20Est. Completion: 2026-06-01
Enrollment target: 120,000 participants Locations- Brigham and Women's Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Pancreatitis, Chronic; Diabetes; Transplant
Patients with severe chronic pancreatitis may be candidates to have their pancreas removed and their islets transplanted…
Minneapolis, United StatesCompleted Jul 1, 2023
Recruiting
Type 2 DiabetesDiabetes Mellitus Type 2
AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood…
Izmir, Turkey (Türkiye)Est. completion Mar 30, 2027